<DOC>
	<DOCNO>NCT02282176</DOCNO>
	<brief_summary>The aim TINN2 study evaluate efficacy azithromycin prevention bronchopulmonary dysplasia preterm neonate .</brief_summary>
	<brief_title>TINN2 : Treat Infection NeoNates 2</brief_title>
	<detailed_description>In contrast situation adult , medicine use treat child Europe test authorise use child . In particular , 46 % medicine prescribe child hospital either unlicensed age group , license , prescribed label . Of child receive least one medication hospital , 67 % receive unlicensed off-label drug , context intensive care , rise 90 % patient . The new Paediatric Regulation enter force early 2007 ensure medicine use child high quality , ethically evaluate authorise appropriately . The Paediatric-Use Marketing Authorisation ( PUMA ) new type marketing authorisation drug cover patent , already available market adult . PUMA apply medicine lack information and/or appropriate formulation child age . Thus , European Medicines Agency ( EMA ) publish list drug , azithromycin belongs , priority medicinal product need evaluation paediatric population . Bronchopulmonary dysplasia ( BPD ) specific disease prematurity accompany pulmonary inflammation . Multiple factor may contribute occurrence BPD . In infant risk develop CLD , one frequent find colonisation preterm lung microbe Ureaplasma . Two Meta-Analyses recent study suggest association presence pulmonary Ureaplasma development BPD . Azithromycin macrolide antibiotic active Ureaplasma spp anti-inflammatory property . Thus , may effective reduce severity bronchopulmonary disease infection inflammation play role . TINN2 project : aim TINN2 study evaluate efficacy azithromycin prevention bronchopulmonary dysplasia preterm neonate . TINN2 consortium involve European leader neonatology , paediatric pharmacology , methodology several SMEs establish link ethical body regulatory authority .</detailed_description>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<criteria>1 . Preterm , 28w + 6d gestational age ( i.e . 28 week 6 day , include infant born one multiple birth ) 2 . Requirement respiratory support within 12hrs birth ( intubate , noninvasive mechanical ventilation include continuous positive airway pressure ) 3 . Presence indwell intravenous line drug administration 4 . Inborn , bear site within recruit centre 's neonatal network follow possible 1 . In opinion PI , baby unlikely survive 48 hour birth 2 . Exposure another macrolide antibiotic 3 . Presence major surgical congenital abnormality ( include patent ductus arteriosus patent foramen ovale ) 4 . Infants born part multiple pregnancy three ( i.e . triplet ) 5 . Contraindication azithromycin specify summary characteristic product . 6 . Participation clinical trial involve Investigational Medicinal Products ( IMPs )</criteria>
	<gender>All</gender>
	<minimum_age>23 Weeks</minimum_age>
	<maximum_age>28 Weeks</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Neonates</keyword>
	<keyword>Preterm</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Ureaplasma</keyword>
	<keyword>Chronic Lung disease</keyword>
	<keyword>Bronchopulmonary dysplasia</keyword>
</DOC>